DE60033310D1 - Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung - Google Patents

Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung

Info

Publication number
DE60033310D1
DE60033310D1 DE60033310T DE60033310T DE60033310D1 DE 60033310 D1 DE60033310 D1 DE 60033310D1 DE 60033310 T DE60033310 T DE 60033310T DE 60033310 T DE60033310 T DE 60033310T DE 60033310 D1 DE60033310 D1 DE 60033310D1
Authority
DE
Germany
Prior art keywords
preparation
methods
receptor antagonists
adenosine receptor
adenosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60033310T
Other languages
English (en)
Other versions
DE60033310T2 (de
Inventor
E Dowling
Carol Ensinger
Gnanasambandam Kumaravel
C Petter
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen Inc
Biogen MA Inc
Original Assignee
Biogen Idec Inc
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Biogen Idec MA Inc filed Critical Biogen Idec Inc
Publication of DE60033310D1 publication Critical patent/DE60033310D1/de
Application granted granted Critical
Publication of DE60033310T2 publication Critical patent/DE60033310T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
DE60033310T 1999-11-12 2000-11-13 Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung Expired - Lifetime DE60033310T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16528399P 1999-11-12 1999-11-12
US165283P 1999-11-12
PCT/US2000/031100 WO2001034604A2 (en) 1999-11-12 2000-11-13 Adenosine receptor antagonists and methods of making and using the same

Publications (2)

Publication Number Publication Date
DE60033310D1 true DE60033310D1 (de) 2007-03-22
DE60033310T2 DE60033310T2 (de) 2007-11-22

Family

ID=22598257

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60033310T Expired - Lifetime DE60033310T2 (de) 1999-11-12 2000-11-13 Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung

Country Status (33)

Country Link
US (4) US6605600B1 (de)
EP (2) EP1230241B1 (de)
JP (1) JP2003513976A (de)
KR (1) KR100845488B1 (de)
CN (1) CN1187354C (de)
AT (1) ATE353328T1 (de)
AU (1) AU784528B2 (de)
BG (1) BG106693A (de)
BR (1) BR0015540A (de)
CA (1) CA2390590C (de)
CY (1) CY1106560T1 (de)
CZ (1) CZ20021615A3 (de)
DE (1) DE60033310T2 (de)
DK (1) DK1230241T3 (de)
EA (1) EA010260B1 (de)
EE (1) EE200200248A (de)
ES (1) ES2281367T3 (de)
GE (1) GEP20043267B (de)
HK (1) HK1049153B (de)
HU (1) HUP0203371A3 (de)
IL (1) IL149486A0 (de)
IS (1) IS6380A (de)
MX (1) MXPA02004795A (de)
NO (1) NO20022237L (de)
NZ (2) NZ519427A (de)
PL (1) PL198156B1 (de)
PT (1) PT1230241E (de)
SK (1) SK6622002A3 (de)
TR (1) TR200301062T2 (de)
UA (1) UA77937C2 (de)
WO (1) WO2001034604A2 (de)
YU (1) YU33702A (de)
ZA (1) ZA200203702B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI229674B (en) 1998-12-04 2005-03-21 Astra Pharma Prod Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses
JP2003513982A (ja) * 1999-11-12 2003-04-15 バイオジェン インコーポレイテッド アデノシンレセプターアンタゴニストとしてのポリシクロアルキルプリン
AU784528B2 (en) * 1999-11-12 2006-04-27 Biogen Idec Ma Inc. Adenosine receptor antagonists and methods of making and using the same
JP2005533054A (ja) * 2002-06-12 2005-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド アデノシンレセプターアンタゴニストを使用して虚血再灌流障害を処置する方法
US20040106797A1 (en) * 2002-07-19 2004-06-03 Pascal Druzgala Novel xanthines having adenosine A1-receptor antagonist properties
US20040229901A1 (en) * 2003-02-24 2004-11-18 Lauren Otsuki Method of treatment of disease using an adenosine A1 receptor antagonist
EP1615894A2 (de) * 2003-04-14 2006-01-18 Pfizer Products Inc. 3-azabizyklo(3.2.1)oktanderivate
KR20060004959A (ko) * 2003-04-25 2006-01-16 노바카르디아, 인코포레이션 신장 기능 저하를 갖는 개별 대상자의 이뇨 작용 개선 방법
JP4859666B2 (ja) * 2003-06-06 2012-01-25 エンダセア， インコーポレイテッド Ａ１アデノシンレセプターアンタゴニスト
WO2007103776A2 (en) * 2006-03-02 2007-09-13 Cv Therapeutics, Inc. A2a adenosine receptor antagonists
CN101420958A (zh) * 2006-04-06 2009-04-29 挪瓦卡尔迪阿公司 共投与腺苷a1受体拮抗剂和抗惊厥药
MX2008014672A (es) 2006-05-19 2009-03-09 Abbott Lab Derivados de alcano azabiciclico sustituidos con bicicloheterociclo fusionado activos en el sistema nervioso central.
EP2035009A1 (de) * 2006-06-16 2009-03-18 Novacardia, Inc. Dauerhafte verbesserung der nierenfunktion mit seltener verabreichung eines aa1ra
US20080242684A1 (en) * 2007-03-29 2008-10-02 Howard Dittrich Methods of administration of adenosine a1 receptor antagonists
US20090197900A1 (en) * 2007-03-29 2009-08-06 Howard Dittrich Methods of treating heart failure and renal dysfunction in individuals with an adenosine a1 receptor antagonist
US20090228097A1 (en) * 2008-03-07 2009-09-10 Abbott Cardiovascular Systems Inc. A1 Adenosine Receptor Antagonist-Coated Implantable Medical Device
CN114790164B (zh) 2021-08-13 2022-12-27 苏州璞正医药有限公司 一种取代的异吲哚啉-1,3-二酮类pde4抑制剂及其药物用途

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3155664A (en) * 1959-11-13 1964-11-03 Endo Lab Derivatives of theophylline
DE3843117A1 (de) 1988-12-22 1990-06-28 Boehringer Ingelheim Kg Neue xanthinderivate mit adenosin-antagonistischer wirkung
JPH06102662B2 (ja) * 1989-09-01 1994-12-14 協和醗酵工業株式会社 キサンチン誘導体
US5290782A (en) 1989-09-01 1994-03-01 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
EP0423805B1 (de) 1989-10-20 2000-08-23 Kyowa Hakko Kogyo Kabushiki Kaisha Kondensierte Purinderivate
DE4019892A1 (de) * 1990-06-22 1992-01-02 Boehringer Ingelheim Kg Neue xanthinderivate
CA2061544A1 (en) 1991-02-25 1992-08-26 Fumio Suzuki Xanthine compounds
ATE180482T1 (de) 1991-11-08 1999-06-15 Kyowa Hakko Kogyo Kk Xanthinderivate zur behandlung der demenz
JPH05294966A (ja) 1992-02-17 1993-11-09 Kyowa Hakko Kogyo Co Ltd キサンチン誘導体
US5342841A (en) 1992-03-12 1994-08-30 Kyowa Hakko Kogyo Co., Ltd. Xanthine derivatives
TW252044B (de) 1992-08-10 1995-07-21 Boehringer Ingelheim Kg
WO1994016702A1 (en) 1993-01-26 1994-08-04 Kyowa Hakko Kogyo Co., Ltd. Remedy for irregular bowel movement
US5395836A (en) 1993-04-07 1995-03-07 Kyowa Hakko Kogyo Co., Ltd. 8-tricycloalkyl xanthine derivatives
US5446046A (en) * 1993-10-28 1995-08-29 University Of Florida Research Foundation A1 adenosine receptor agonists and antagonists as diuretics
WO1998057645A1 (fr) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Medicament contre l'oedeme hepatique
WO1998057644A1 (fr) 1997-06-16 1998-12-23 Kyowa Hakko Kogyo Co., Ltd. Agent de prevention et remede contre la nephropathie induite par les medicaments
DE19816857A1 (de) 1998-04-16 1999-10-21 Boehringer Ingelheim Pharma Neue unsymmetrisch substituierte Xanthin-Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP0955301A3 (de) * 1998-04-27 2001-04-18 Pfizer Products Inc. 7-Aza-bicyclo[2.2.1]-heptan Derivate, deren Herstellung und Verwendung aufgrund ihrer Affinität für neuronale nikotinische Acetylcholin Rezeptoren
US6489331B1 (en) 1998-07-02 2002-12-03 Kyowa Hakko Kogyo Co., Ltd. Remedies for diabetes
AU784528B2 (en) * 1999-11-12 2006-04-27 Biogen Idec Ma Inc. Adenosine receptor antagonists and methods of making and using the same
JP2003513982A (ja) * 1999-11-12 2003-04-15 バイオジェン インコーポレイテッド アデノシンレセプターアンタゴニストとしてのポリシクロアルキルプリン

Also Published As

Publication number Publication date
AU2042101A (en) 2001-06-06
GEP20043267B (en) 2004-06-25
EP1230241A2 (de) 2002-08-14
WO2001034604A3 (en) 2002-01-10
HK1049153A1 (en) 2003-05-02
NZ527918A (en) 2005-05-27
ES2281367T3 (es) 2007-10-01
HUP0203371A3 (en) 2005-02-28
KR100845488B1 (ko) 2008-07-10
EA200200562A1 (ru) 2002-10-31
PT1230241E (pt) 2007-05-31
BR0015540A (pt) 2002-07-23
MXPA02004795A (es) 2005-07-01
US20050222179A1 (en) 2005-10-06
KR20020049043A (ko) 2002-06-24
NZ519427A (en) 2003-08-29
US20080004293A1 (en) 2008-01-03
US20030225038A1 (en) 2003-12-04
WO2001034604A2 (en) 2001-05-17
IL149486A0 (en) 2002-11-10
EP1775297A2 (de) 2007-04-18
CA2390590C (en) 2010-03-16
SK6622002A3 (en) 2003-02-04
EP1230241B1 (de) 2007-02-07
EP1775297A3 (de) 2008-12-03
NO20022237L (no) 2002-07-12
DK1230241T3 (da) 2007-06-04
US6605600B1 (en) 2003-08-12
YU33702A (sh) 2005-03-15
NO20022237D0 (no) 2002-05-10
TR200301062T2 (tr) 2003-09-22
CN1187354C (zh) 2005-02-02
PL356044A1 (en) 2004-06-14
PL198156B1 (pl) 2008-05-30
CZ20021615A3 (cs) 2002-08-14
HK1049153B (zh) 2007-09-28
ATE353328T1 (de) 2007-02-15
IS6380A (is) 2002-05-10
CY1106560T1 (el) 2012-01-25
HUP0203371A2 (hu) 2003-02-28
ZA200203702B (en) 2003-10-29
BG106693A (bg) 2003-01-31
UA77937C2 (en) 2007-02-15
CA2390590A1 (en) 2001-05-17
EA010260B1 (ru) 2008-06-30
JP2003513976A (ja) 2003-04-15
CN1399636A (zh) 2003-02-26
DE60033310T2 (de) 2007-11-22
EE200200248A (et) 2003-06-16
AU784528B2 (en) 2006-04-27

Similar Documents

Publication Publication Date Title
CY1110512T1 (el) Πολυκυκλοαλκυλοπουρινες ως ανταγωνιστες υποδοχεων αδενοσινης
DE60033310D1 (de) Adenosin rezeptor antagonisten sowie methoden zu deren herstellung und verwendung
NO920945D0 (no) Nye 8-substituerte puriner som selektive adenosinreseptormidler
CA2275686A1 (en) Isoquinolinamine and phthalazinamine derivatives which interact with crf receptors
NZ533358A (en) 3,4-Dihydro-1H-isoquinolin-2-yl-derivatives for use as NK2 receptor antagonists
ATE256126T1 (de) 5-heteroatom-alkyl substituierte 3-oxo-pyrido(1,2-a)benzimidazol-4-carboxamid derivate zur behandlung zentral nervöser system störungen

Legal Events

Date Code Title Description
8364 No opposition during term of opposition